{"entity":{"id":"joel-guigay","kind":"person","name":"Joël Guigay","aka":[],"tldr":"Nice oncologist who led TPExtreme, the GORTEC trial that showed the shorter TPEx regimen is a reasonable alternative to EXTREME for recurrent or metastatic head and neck cancer.","summary":"Joël Guigay is a medical oncologist at Centre Antoine Lacassagne in Nice and a leader of the French GORTEC head and neck group. He was first author of the 2021 Lancet Oncology report of TPExtreme, the phase 2 trial comparing docetaxel, cisplatin and cetuximab (TPEx) with the EXTREME regimen as first-line treatment for recurrent or metastatic head and neck squamous-cell carcinoma; TPEx did not lengthen survival but was less toxic and shorter, and is used as an alternative.","asOf":"2026-09-18","links":[],"tags":["head-and-neck","trialist"],"related":[],"cancers":["recurrent-metastatic-hnscc","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["centre-antoine-lacassagne"],"pathways":[],"terms":[],"trials":["tpextreme"],"people":[],"bottlenecks":[],"keyPapers":["paper-tpextreme-lancet-oncol-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Centre Antoine Lacassagne, Nice","institutionId":"centre-antoine-lacassagne","specialisms":["Head and neck cancer","Chemotherapy regimens","GORTEC trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Guigay%5BAuthor%5D"}],"papers":[]},"route":"/people/joel-guigay/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/"}],"institution":[{"id":"centre-antoine-lacassagne","kind":"institution","name":"Centre Antoine Lacassagne","route":"/institutions/centre-antoine-lacassagne/"}],"trial":[{"id":"tpextreme","kind":"trial","name":"TPExtreme (GORTEC 2014-01)","route":"/trials/tpextreme/"}],"paper":[{"id":"paper-tpextreme-lancet-oncol-2021","kind":"paper","name":"TPExtreme (GORTEC 2014-01): docetaxel, cisplatin and cetuximab versus the EXTREME regimen in recurrent or metastatic head and neck cancer","route":"/key-papers/paper-tpextreme-lancet-oncol-2021/"}]}}